**DASON COVID-19 Weekly Treatment Literature Update 10/9/2020**

Prepared by: Angelina Davis, PharmD, MS, April Dyer, PharmD, MBA, MSCR, Elizabeth Dodds Ashley, PharmD, MHS, Melissa Johnson, PharmD, MHS, S. Shaefer Spires, MD, Travis Jones, PharmD

The following summarizes key literature pertaining to treatment of COVID-19 during the past week.

*Note: some of the data discussed below may be in pre-print form that has not yet been peer-reviewed. We have noted some discrepancies in some of this data, and final printed versions may ultimately differ from what is shown here. We will update as soon as possible; caution is advised when interpreting this literature.

**NIH Guideline Updates**

No updates this week.

**Therapeutic Information**

The American College of Physicians published guidance on remdesivir Use:

Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1)

Link: [https://www.acpjournals.org/doi/10.7326/M20-5831](https://www.acpjournals.org/doi/10.7326/M20-5831)

Both Eli Lilly and Regeneron are seeking emergency use authorization for their monoclonal antibody products. Early reports are that if approved, distribution would be through the Federal government and initially free of charge. We will let you know if we hear additional information.

**New Literature This Week**

Updated studies with data from the ACTT-1 trial of remdesivir and the RECOVERY trial of multiple treatments conducted in the UK were published this week.


RECOVERY Trial results showed no benefit to hospitalized patients receiving:
- lopinavir-ritonavir (The Lancet: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext)).

Additional data on the ACTT-2 trial (remdesivir +/- baricitinib) supporting original findings of improved time to recovery and a numerical (but not statistical) difference in mortality favoring baricitinib, with greatest results in patients requiring supplement oxygen or non-invasive ventilation at baseline. The data were provided via press release: [https://investor.lilly.com/news-releases/news-release-details/baricitinib-has-significant-effect-recovery-time-most-impactful](https://investor.lilly.com/news-releases/news-release-details/baricitinib-has-significant-effect-recovery-time-most-impactful)
Treatment Summary Tables

The remdesivir summary table with the information of published studies to date can be found at this link:

The hydroxychloroquine summary table is available at this link:

The tocilizumab summary table with the information of published studies to date can be found at this link

The convalescent plasma summary table is available at this link:

All FAQs available here: https://dason.medicine.duke.edu/covid-19-novel-coronavirus-resources